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Key Points
• The proportion of Treg
cells is increased in
patients with mixed
chimerism after SCT
and acts to suppress
the alloreactive immune
response.
•Host and donor cells
both contribute to the
expanded Treg cell
pool in this setting.
Transplantation is an effective treatment ofmany clinical disorders, but themechanisms that
regulate immunological tolerance are uncertain and remain central to improving patient
outcome. Hemopoietic stem cell transplantation (SCT) often establishes “mixed chimerism”
in which immune cells from both the donor and patient coexist in vivo in a setting of
immunological tolerance. We studied immune function in 69 patients within 2 months
following SCT; 37 were fully donor and 32 displayed mixed chimerism. The proportion of
T regulatory (Treg) cells was increased during mixed chimerism and comprised equal
numbers of donor and host-derived regulatory cells. This was associated with a tolerogenic
PD-L11 proﬁle on dendritic cells. Importantly, effector T cells from patients with mixed
chimerism exhibited reduced cytotoxicity against host target cells in vitro, but this was
restored following depletion of CD41 Treg cells. These data show that Treg cells play a major
role in sustaining immunological tolerance during mixed chimerism. These insights
should help to guide novel interventions to improve clinical transplantation.
Introduction
The ultimate goal of transplantation immunology is the generation of tolerance to allogeneic tissue in the
absence of long-term immunosuppression and with intact third-party immunity. Operational tolerance
was first demonstrated in fraternal bovine twins that shared a placental circulation and was termed
“mixed hemopoietic chimerism.”1 Active induction of mixed chimerism (MC) to promote tolerance
toward donor antigens was achieved by transplanting allogeneic hemopoietic stem cells into neonatal
mice,2 but the establishment of MC to facilitate allogeneic transplantation in adult humans has proven
to be a significant challenge.3-8
Clinical regimens to induce MC rely on reduced-intensity conditioning protocols together with T-cell
depletion or costimulatory blockade, which reduce host resistance without eliminating host hemopoiesis.6-8
However, the mechanisms that mediate chimeric tolerance in this setting remain undefined. Studies
within patients have shown that MC does not have to be maintained indefinitely or allografts to be
tolerated long-term,9 which suggests that thymic (central) deletion of alloreactive T cells is not sufficient
to explain sustained chimerism in this setting, despite a major role in murine models.10 Indeed, studies
have suggested that suppression mediated by regulatory T cells or monocytoid cells11 or the induction
of peripheral anergy9,12 may be more important.
MC is observed frequently following reduced-intensity conditioned allogeneic hemopoietic stem cell
transplantation (allo-HSCT) for hematological malignancies,13-17 particularly when in vivo T-cell depletion is
incorporated into the conditioning regimen.18-22 T-cell depletion is used in this setting to suppress the
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alloreactive immune response and reduce the risk of graft-versus-
host disease (GVHD). However, allo-reactive immune responses
also underlie the graft-versus-leukemia effect, and because
disease relapse remains the major clinical challenge in allo-HSCT, it
is imperative that the degree of T-cell depletion is titrated according
to clinical risk.23,24
In this study, we investigated the mechanisms of immune tolerance
in a cohort of patients with stable mixed T-cell chimerism originating
early posttransplant. We show that T regulatory (Treg) cells, derived
from both the patient and the donor, play the dominant role in
suppression of alloreactive immune responses in this setting. These
findings suggest a range of potential options to modulate immune
tolerance in the early posttransplant period.
Materials and methods
Study participants
Patients with acute myeloid leukemia undergoing reduced-intensity
conditioned allo-HCT between 2013 and 2017 were eligible
for investigation (supplemental Table 1). All patients received
10 mg/d alemtuzumab from day 25 pre-HSCT for 5 days,
fludarabine (30 mg/m2 for 5 days), melphalan (140 mg/m2 for
1 day), and posttransplant cyclosporin A for GVHD prophylaxis.
Antimicrobial prophylaxis and viral monitoring were carried out
according to standard institutional policies. Analyses of peripheral
bloodmononuclear cell (PBMC) and T-cell chimerismwere performed
at 50 days posttransplant as described previously.19
Flow cytometry
PBMCs were isolated by density gradient centrifugation using
lymphocyte cell separation media (Cedarlane). Cell populations
were analyzed using multiparameter flow cytometry (supplemental
Table 2 antibody list). Mononuclear cells were stained with antibodies
on ice for 20 minutes, protected from light, washed in MACs buffer
(Sigma-Aldrich), and compared with unstained controls. For Treg
analysis, cells were surface stained and then fixed, permeabilized,
and stained for intranuclear FoxP3 expression using the eBioscience
FoxP3/Transcription factor staining buffer set (Thermofisher). An
example gating strategy for Treg cells is shown in supplemental
Figure 1A. Dead cells were discriminated using propidium iodide
(BD Biosciences) or fixed viability dyes (eBioscience). Data were
acquired on a Gallios flow cytometer (Beckman Coulter) and ana-
lyzed using Kaluza, version 1.3, software. Absolute T-cell counts
were calculated by multiplying the percentage of T cells (from
all lymphocytes) by the clinically derived lymphocyte count obtained
from the same bleed (3109/L).
Detection of KDM5D messenger RNA
To assess the composition of host and donor cellular compart-
ments, 1 3 106 post-HSCT PBMC were cell surface–stained
and subjected to the PrimeFlow RNA assay (eBioscience) per
the manufacturer’s instructions. A b-2M housekeeper probe and
a customized KDM5D probe (to discriminate between male and
female cells) were used in all analyses, whereas a FoxP3 probe
was added to assess Tregs. To gain sensitivity, target probe
hybridization was extended to 3 hours, whereas preamplification,
amplification, and label probe hybridization steps were extended
to 2 hours each. Examples of the gating strategy and control
experiments are shown in supplemental Figure 1B-C.
Post-HSCT T-cell responses to HLA-DR1
cell stimulation
In vitro coculture was adapted from Jedema et al.25 Stimulator
HLA-DR1 cells were enriched from pre-HSCT patient PBMC
samples (.90% purity) using anti-HLA-DR magnetic beads (Miltenyi
Biotech). These were irradiated (30 Gy) to prohibit proliferation and
alteration of the final stimulator:effector cell ratio. T cells (.98%
purity) were obtained using negative magnetic selection (Stem Cell
Technologies, Cambridge, United Kingdom) from post-HSCT PBMCs.
For patients displaying MC, T cells were also depleted of CD25
expressing Tregs, using anti-CD25 magnetic beads (.95% pure;
Miltenyi Biotech). T cells were labeled with 10 mM/1 3 106 cells
Violet cell tracer (VCT; Invitrogen) for 20 minutes at 37°C. The
reaction was stopped by adding RPMI 1640 media containing 10%
fetal calf serum. After 2 washes, 1 3 105 T cells were cultured at a
1:1 ratio with HLA-DR1 stimulator host cells in RPMI 1640 media
supplemented with penicillin and streptomycin, L-glutamine, and
10% fetal calf serum. Cultures were set up in triplicate and
incubated at 37°C for 5 days. Upon harvest, death was assessed
with propidium iodide, and the number of stimulator and responder
cells assessed in comparison with a known quantity of Accu-Chek
counting beads (Molecular Probes, Invitrogen). An index of in vitro
cytotoxicity, defined as the percentage of remaining stimulator
patient-derived HLA-DR1 cells divided by the percentage of
remaining responder posttransplant VCT1 T cells, was then
generated. An example of the gating strategy is shown in
supplemental Figure 2A. The relative survival of HLA-DR1
antigen-presenting cells (APCs) and T cells during culture is
shown in supplemental Figure 2B.
Statistical analyses
Summarizedmeans of grouped data were analyzed by 2-way analysis of
variance (ANOVA) with post hoc Tukey tests. One-way ANOVA or
Kruskal-Wallis tests with post hoc Dunn tests compared means across
3 groups; unpaired Student t tests, Mann-Whitney U analyses, and
Wilcoxon matched pair signed rank tests did likewise across 2 groups.
Analyses were undertaken using Prism software (GraphPad). The
effect of chimerism on overall survival was estimated using the
Kaplan-Meier method and log-rank test. Chimerism was treated as a
baseline variable using a landmark analysis. The effect of chimerism
on time-to-event outcomes with competing risks (relapse and GVHD)
was estimated by the Gray method. These calculations were
performed with R 2.14.1 (the R project for Statistical Computing).
Study approval
Clinical data and samples were obtained following written informed
consent (in accordance with the Declaration of Helsinki) to the
Biological Correlates of Stem-cell Transplantation study and
approved by the South Birmingham Research Ethics Committee
(no. Q5/1Q2707/175).
Results
MC is established following T cell–depleted allo-HSCT
A total of 69 consecutive patients undergoing reduced-intensity
conditioned allo-HSCT for the treatment of acute myeloid leukemia
was recruited into the study; blood samples were taken at 4 to
8 weeks after transplant. The proportion of donor and host cells
within both the PBMC and T-cell compartments was measured
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using variable number of tandem repeats–specific polymerase
chain reaction. The detection limit of the assay was 1%; as
such, $99% donor chimerism was considered to be “fully donor,”
whereas #98% donor chimerism constituted MC.
Thirty-seven patients (54%) were fully donor in both the PBMC and
T-cell fractions (full chimerism [FC]), whereas 32 patients (46%)
demonstrated MC in PBMC and/or T cells (Figure 1A). The degree
of chimerism varied within MC patients, although the percentage
of donor cells in the PBMC fraction was generally greater than the
T-cell fraction. Indeed, the ratio of donor to host T cells was 1.2:1,
indicating similar proportions of donor and host-derived T cells
within patients at this early time point. Interestingly, this pattern of
T-cell MC was stable, and no patients spontaneously converted
to FC within the first 6 months (Figure 1B-C). Donor lymphocyte
infusions were administered at 6 months if MC persisted, according
to institutional protocol. No differences in the proportion of CD561
natural killer cells or CD191 B cells were seen within the 2 groups
(data not shown).
DCs are less activated and express a tolerogenic
PD-L11 phenotype in patients with MC
Dendritic cells (DCs) are pivotal in priming immune responses;
to interrogate the mechanisms that may regulate MC, we initially
investigated the phenotype of CD11c1 conventional (cDC) and
CD1231 plasmacytoid DC (pDC) in relation to chimerism.
The ratio of cDC to pDC was 2.5:1 in FC and MC patients
(Figure 2A). CD86 is a marker of activation on DC, and a markedly
reduced proportion of CD861 DC was observed in patients
with MC compared with those with FC (MC 58% vs FC 81%;
P 5 .0068; Figure 2B).
PD-L1 and PD-L2 play important roles in the promotion of
tolerogenic function by DC and impair T-cell immunity to minor
histocompatibility antigens with subsequent attenuation of the
graft-versus-leukemia response.26-28 Interestingly, PD-L1 expres-
sion was twice as high on DC from patients with MC compared
with those with FC (41% vs 18%, P5 .0052; Figure 2C). This was
most pronounced in cDC (P 5 .0053; Figure 2D), although a
similar trend was also observed within the pDC subset. Expression
of PD-L2 did not vary between different groups (4.3% FC vs 7%
MC; Figure 2C).
A challenge in clinical studies has been to directly visualize donor or
host cells to assess the effect of chimerism on individual immune
lineages. To accomplish this, we used PrimeFlow RNA in patients
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Figure 1. PBMC and T-cell donor chimerism following HSCT. (A) Bubble
chart demonstrating PBMC and T-cell donor chimerism levels at day 50 posttrans-
plant. The area of each bubble represents the number of events. The first group
(n 5 37, red), displayed FC, in which both PBMC and T-cell donor chimerism
was $99%. The second group (MC, n 5 32, blue) demonstrated MC in both PBMC
and T-cell fractions (PBMC and T-cell chimerism #98%). The pattern of PBMC
donor chimerism up to day 365 according to donor chimerism at day 50 posttrans-
plant. PBMC chimerism remained stable at complete (or near complete) donor
chimerism in patients who demonstrated FC by day 50 posttransplant. In contrast,
Figure 1. (continued) PBMC donor chimerism remained significantly lower in those
found to have MC at day 50, even beyond the initiation of donor lymphocyte infusion
(DLI) at day 180 (****P , .0001; 2-way ANOVA, with post hoc Tukey test, mean,
and standard error shown for all data points; FC, n 5 37; MC, n 5 32). (B) The
pattern of T-cell donor chimerism up to day 365 according to donor chimerism at
day 50 posttransplant. (C) T-cell chimerism remained stable at complete (or near
complete) donor chimerism for the first 100 days in patients who demonstrated
FC by day 50 posttransplant, but displayed an average drop of 10% by day 180.
In contrast, T-cell donor chimerism remained significantly lower in those found to
have MC at day 50 with a trend toward partial correction following instigation of
DLI at day 180 (****P , .0001, 2-way ANOVA, with post hoc Tukey test, mean,
and standard error shown for all data points; FC, n 5 37; MC, n 5 32).
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undergoing gender-mismatched HSCT. This determined cellular
origin according to RNA expression of the KDM5D (SMCY)
gene derived from the Y chromosome and was combined with
conventional immunophenotyping to examine host and donor
DCs using flow cytometry. Interestingly, PD-L1 expression by
donor DC was approximately double that observed on host
DC in patients with MC (average 67% vs 29%; P 5 .0002)
(Figure 2E). Together, these observations show that DC demon-
strate a less activated and more tolerogenic phenotype in the
setting of MC.
Proportion of Treg to nonregulatory CD4 T cells
is increased in patients with MC and comprises
equivalent numbers of host and donor-derived cells
Wewent on to assess potential determinants of peripheral tolerance.
Initially, the frequency of CD41CD251CD127lowFoxP31 Treg cells in
the CD4 T-cell pool was defined. This value was 4.7% in patients
with FC, revealing that effector CD41 T cells are the dominant
population and in keeping with the strong clinical alloreactive
immune responses associated with this group.29 In contrast, the
proportion of Treg cells in patients with MC was almost double
this value at 8.7% (P 5 .03; Figure 3A). No difference was
observed in the absolute number of Treg cells between the
2 groups (Figure 3B), but an inverse correlation was apparent
between the number of Treg cells and the percentage of donor
chimerism (r 520.25, P 5 .04; Figure 3C). PrimeFlow RNA was
used to determine the contribution of donor and host cells to the
expanded Treg compartment in MC donors (supplemental
Figure 2B); we observed comparable numbers of cells from
both sources (Figure 3D). Functional analysis showed that Treg
production of interleukin-10 and transforming growth factor-b was
equivalent between patients with FC and MC (Figure 3E)
Reconstitution of T cells is comparable in patients
with MC and FC
We next assessed the effect of chimerism on the non-Treg T-cell
compartment. Serial analyses were performed within individual
patients to appraise T-cell reconstitution between 4 weeks and
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Figure 2. DCs are less activated and express a tolerogenic PD-L11 phenotype in patients with MC. (A) The contribution and phenotype of cDC and pDC within the
peripheral mononuclear cell compartment at 4 to 8 weeks after allo-HSCT was assessed by flow cytometry. The ratio of cDC:pDC was similar in patients with FC (2.5:1;
n 5 15) or MC (2.6:1; n 5 15). (B) Expression of CD86 on DC in relation to chimerism status. A total of 81% of DC in FC expressed CD86 (n 5 15) compared with only
58% of DC in MC (n 5 15; **P 5 .0068). (C) Expression of PD-L1 and PD-L2 on DC in relation to chimerism status. A total of 41% of DC in MC expressed PD-L1 compared
with 18% of DC in FC (**P 5 .0052; FC, n 5 15; MC, n 5 15). No difference was observed in the level of PD-L2 expression (FC, 4.3%; MC, 7% [not significant]). DCs
therefore appear to have a tolerogenic phenotype in the setting of MC. (D) Expression of PD-L1 on DC subsets. Increased PD-L1 expression was most pronounced on the
cDC subset in MC (47%; n 5 15) compared with cDC in FC (20%; n 5 15; **P 5 .0053), whereas a trend was observed toward increased PD-L1 expression on pDC in MC.
(E) Expression of PD-L1 on host and donor DC in MC. This was determined by combining cell surface phenotyping with RNA probes specific for the KDM5D (SMCY) gene,
derived from the Y chromosome. Host and donor cells were thereby distinguishable in the context of patients undergoing gender-mismatched allo-HSCT. PD-L1 expression
was observed on a mean of 67% donor DC compared with only 29% of host DC (n 5 10; ***P 5 .0002). For graphs with unpaired data, the mean and standard error of the
mean are shown; analyses were undertaken with 2-tailed Mann-Whitney U tests. Paired analysis used a Wilcoxon matched pairs signed rank test.
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1 year after transplant. The total number of T cells remained low
throughout the posttransplant period (data not shown), but no
differences were observed in the magnitude or pattern of CD41
or CD81 T-cell reconstitution between the groups (Figure 3F-G).
The distribution of CD41 or CD81 memory subsets, as determined
by CCR7 and CD45RA expression, was also not influenced by
chimerism status (supplemental Figure 3).
Treg cells inhibit the killing of host cells in MC
We went on to examine the ability of the expanded Treg pool in MC
patients to suppress alloreactive responses in vitro (Figure 4A).
T cells were isolated 4 to 8 weeks after transplant, labeled with VCT,
and cocultured at a 1:1 ratio with irradiated host HLA-DR1 APC
enriched from pretransplant PBMC samples. The relative proportion
of surviving “effector” cells (posttransplant T cells) to “target” cells
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Figure 3. Treg cells comprise a larger proportion of the
CD41 repertoire in patients with MC. (A) The percentage
of CD41CD251CD127lowFoxP31 Treg cells within the CD41
T-cell pool is shown in relation to chimerism status. Patients
with MC demonstrate a higher frequency of Treg cells (8.7%,
n 5 29) compared with patients with FC (4.7%, n 5 35;
*P 5 .03). (B) The absolute number of Treg cells was similar
between FC and MC cohorts at 2.6 3 106/mL (n 5 35) and
2.7 3 106/mL (n 5 29), respectively. (C) The number of Treg
cells is inversely correlated to the degree of donor T-cell
chimerism. Pearson’s coefficient r 5 20.25, *P 5 .04
(n 5 64). (D) The number of host and donor-derived Treg cells
within patients with MC calculated using flowRNA probes
specific to the KDM5D gene on the Y chromosome. No
differences were seen between the 2 groups (n 5 11).
(E) Interleukin-10 and transforming growth factor-b production
by Treg cells from patients with FC and MC. (F) The number
of CD41 T cells within peripheral blood in the first year after
transplant in relation to chimerism status. No differences were
seen between the 2 groups (FC, n 5 35; MC, n 5 29).
(G) The number of CD81 T cells within peripheral blood in the
first year after transplant in relation to chimerism status. No
differences were seen between the 2 groups (FC, n 5 35;
MC, n 5 29). All graphs show the mean and standard error.
Analyses were undertaken with 2-tailed Mann-Whitney U tests
(A-B) and Wilcoxon matched pairs signed rank test (C).
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(host APC) was reassessed 5 days later. In MC, APC persisted in
coculture with T cells and generated an effector:target ratio of 1:5
in patients with MC because of the relative increased survival
of target cells compared with T cells. In contrast, this ratio fell to
1:1.3 in patients with FC (P 5 .011; Figure 4B). Importantly,
negligible T-cell proliferation was observed in either culture over
this period (supplemental Figure 2C), and the relative survival
of T cells was also equivalent within FC and MC cocul-
tures (supplemental Figure 2B). As such, this difference in the
effector:target ratio can be attributed directly to T cell–mediated
lysis of the APC population.
Cocultures from MC patients contain autologous effector T cells
that would not be expected to demonstrate alloreactive recog-
nition. To determine whether Treg cells are actively suppressing
alloreactive responses in this patient group, we next depleted
CD251 cells before culture of T-effector cells with host APC.
This led to substantially increased lysis of host APC target cells
(Figure 4C), indicating that Treg cells do indeed suppress donor
alloreactive immune responses in patients with MC. Importantly,
CD251 T-cell depletion before coculture using T cells derived from
fully donor patients did not mediate increased killing of target APC
(supplemental Figure 2D).
Discussion
MC can provide a robust tolerogenic platform for allogeneic
transplantation,3,5 but the mechanisms that regulate immune
tolerance in this setting remain unclear. MC of only short-term
duration after allo-HSCT may establish tolerance for subsequent
kidney transplantation29; our study therefore focused on immune
regulation in the first 2 months following hemopoietic transplantation
when the allogeneic immune response is established.30-34
Priming of the allogeneic immune response is dominated by “direct”
host DC stimulation of donor T cells,35 although “indirect” antigen
presentation by donor DC can also play a role.36 We observed that
DCs are less activated during MC, and this may underlie the
associated findings of an increased proportion of regulatory T cells
and reduced alloreactive function in this setting. Tolerogenic DC do
indeed play a role in limiting the alloreactive response,27 andPD-1/PD-L1
signaling is an important underlying mechanism.37 We also ob-
served that PD-L1 expression is increased on cDC in the setting of
MC and that this pattern is specific to the donor-derived cells. This
suggests that donor DC may play the major role in regulating
allogeneic immune responses during MC and that maturation of
effector alloreactive T cells in this setting may arise from direct
presentation on host APC.
Morris et al38 have recently used an elegant approach based
on T-cell receptor sequence analysis of alloreactive T cells to
demonstrate that alloreactive cells are eliminated in patients with
MC, but it is important to note that this effect was not seen until
6 months posttransplant.
These findings suggest an important role for peripheral tolerance
mediated by Treg cells in MC, particularly early following transplant.
This concept is supported by animal models that show that either
A
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Figure 4. Treg cells limit cytotoxic alloreactive immune re-
sponses in the setting of MC. (A) Irradiated host HLA-DR1 APCs
were cocultured with responder T cells isolated posttransplant. Cells
were cocultured at a ratio of 1:1 for 5 days and then the number of
residual live cells was determined by propidium iodide and Accu-Chek
counting beads. An index of in vitro cytotoxicity was then defined as the
percentage of remaining stimulator host HLA-DR11 cells divided by the
percentage of remaining responder T cells. (B) Ratio of host HLA-DR1
cells: post-HSCT T cells, 1.3: 1 in the context of FC compared with
5:1 in the context of MC (*P 5 .011), indicating that T cells from
patients with MC are less able to eliminate HLA-DR11 APCs. The
mean and standard error are shown, and analysis was undertaken
with a 2-tailed Mann-Whitney U test (FC, n 5 11; MC, n 5 12).
(C) Coculture assays were reestablished from patients with MC
following depletion of CD251 cells (Treg cells) before in vitro culture.
The ratio of host HLA-DR11 cells to T cells was significantly
decreased, indicating that Treg cells act directly to suppress donor
alloreactive cytotoxicity in the context of MC (*P 5 .0312). The mean
and standard error are shown; analysis was undertaken with a
Wilcoxon matched pairs signed rank test (n 5 7).
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host or donor-derived Treg cells can facilitate hemopoietic stem cell
engraftment,39 and that the adoptive transfer of Treg cells directly
facilitates bone marrow engraftment in reduced-intensity pro-
tocols.40 Nonhuman primate models have also shown that Treg
cells are required to establish tolerance following nonmyeloa-
blative conditioning regimens.5,41 Clinically, T-cell function is deliber-
ately modulated early posttransplant to prevent severe GVHD,
and increased exposure to cyclosporin in the first 21 days after
transplant is an independent risk factor for relapse.40 However,
we did not observe a difference in the average area under the
curve of trough cyclosporin level according to chimerism (supplemental
Figure 4), suggesting that the differences we observed in MC
occur in the presence of immunosuppression.
We observed a twofold increase in Treg cells to non-Treg CD4
T cells in patients with MC compared with those who were fully
donor. Importantly, both host and donor cells contributed to this
population, suggesting that the presence of residual host Treg
cells may play a pivotal role in maintaining chimeric tolerance.
Indeed, attenuation of antitumor responses by residual host Treg
cells has been previously demonstrated42,43 and indicates their
potential potency in regulation of alloreactive immunity. In contrast,
murine and clinical studies involving the adoptive transfer of donor
Treg cells show that these can suppress GVHD while maintaining
graft-versus-leukemia responses.44-46 Similarly, in our study, patients
with MC exhibited a 3.5-fold increased risk of disease relapse
(supplemental Figure 5B; P , .001) and a reciprocal three-
fold decreased risk of acute GVHD (supplemental Figure 5C;
P5 .005), although the cohort was too small to permit meaningful
multivariate analysis. Nevertheless, the association between MC
and increased risk of disease relapse has not been seen in all
studies, and our findings suggest that the relative contribution of
host and donor Treg cells may be an additional factor to consider
in this regard.
The Treg cells present after transplant might derive from recent
thymic emigration5 or peripheral conversion from T-effector cells.
Interestingly, alemtuzumab can drive the generation of Treg cells
in vitro, and T-cell immune reconstitution following alemtuzumab
therapy is characterized by early expansion of Treg cells.47-49 As
such, its incorporation within the conditioning protocol may well
provide a direct explanation for the relatively high incidence of MC
in the patient cohort.
Overall, our data support a model whereby MC is characterized by
the retention of host DC and Treg cells, which in turn limit donor
DC activation and promote a tolerogenic phenotype. Subsequent
alloreactive T-cell responses generated from naive donor T cells
are not fully activated and, in combination with active Treg cell
suppression, the allogeneic immune response is inhibited (Figure 5).
It will be important in future studies to assess the effect of these
factors on chimerism within other immune subsets such as natural
killer and B cells.
A striking finding in our study was that alloreactive T-cell elimination
of host cells in vitro was less effective in the setting of MC but was
fully restored following the depletion of Treg cells. This provides
strong support for the concept of active suppression of alloimmune
responses in MC following allo-HSCT and raises a number of
potential therapeutic options. Therapeutic conversion to FC is
considered important in patients with stable MC to limit disease
direct antigen presentation
donor T cell
host T cell
donor antigen
host antigen
donor alloreactive T cell
host alloreactive T cell
donor regulatory T cell
host regulatory T cell
donor dendritic cell
host dendritic cell
PD-L1
PD-L1
PD-L1
Key:
Immune competent host
Full donor chimerism
Mixed donor chimerism
host tissueA
B
C
Figure 5. A model for the maintenance of MC following
allo-HSCT. (A) In an immunocompetent host, donor cells are
processed by host DC and presented to host T cells, which then
eliminate residual donor cells. This scenario can occur following
entry of fetal cells into the maternal circulation during pregnancy
or during rejection of solid organ grafts. (B) In the setting of
profound host immune suppression following allo-HSCT, all host
T cells are eliminated by conditioning so that a host alloreactive
response to donor cells is abrogated. Instead, donor T cells
recognize host peptide/major histocompatibility complex com-
plexes on DC; this alloreactive response leads to both GVHD and
the graft-versus-leukemia effect. (C) MC may be established in the
setting of moderate host immune suppression following allo-HSCT.
Here, residual host Treg cells may limit the activation of DCs,
which then fail to induce a cytotoxic allogeneic immune response
by donor T cells. Propagation of the allogeneic immune response
is inhibited further by the presence of donor Treg and donor DCs
that are rendered tolerogenic.
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relapse. This is usually attempted through the delivery of donor
leukocyte infusions,30,50,51 but our findings suggest that targeting the
DC compartment, potentially with PD-L1 blockade, might also boost
donor allogeneic immune responses and that the elimination of Treg
cells through agents such as anti-CD25 antibodies might also prove
effective. In addition, although our studies were performed in patients
following hemopoietic transplantation, a degree of MC is seen in
many patients following solid organ transplantation; these observa-
tions might also be instructive in that setting.
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